Innovating Works

BIOMEDCODE S.A.

Desconocido
INFRAPLUS: Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un HORIZON EUROPE: HORIZON-INFRA-2023-DEV-01 In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine...
2024-06-20 - 2027-05-31 | Financiado
INFRAFRONTIER2020: Towards enduring mouse resources and services advancing research into human health and disease BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un H2020: H2020-INFRADEV-2016-2017 The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse...
2016-12-14 - 2021-12-31 | Financiado
BTCURE: BeTheCuRE BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP6: BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
2011-04-01 - 2017-03-31 | Financiado
INFLA-CARE: Understanding inflammation associated tumorigenesis for the rational design of novel anti cancer the... BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7: Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cell...
Financiado
BTCURE: BeTheCuRE BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7: BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
Financiado
MASTERSWITCH: Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7: Objective: To delineate the biological and molecular pathways that initiate and drive chronic inflammatory disease and to transform the know...
Financiado
ADDRESS: Joint training and research network on Chromatin Dynamics and the DNA Damage Response BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7: DNA is tightly wrapped around histones to form chromatin, a highly dynamic structure that can adopt different conformations with contrasting...
Financiado
CodeAge: The role of Chronic DNA damage in Ageing and Age related pathology BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7: Ageing is an inexorable homeostatic failure of largely unknown aetiology that leads to increased vulnerability to disease limiting the quali...
Financiado
TARKINAID: Targeting Src family tyrosine kinases in chronic autoimmune and inflammatory diseases BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS participó en un FP7: The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.